News & Updates
Filter by Specialty:
Exercise, Mediterranean diet remain key against MASLD
A 12-week lifestyle intervention comprising a moderate-intensity physical activity (PA) programme and a hypocaloric Mediterranean diet (MD) promoted fat removal and liver fibrosis improvement in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), findings from the EHmet-DIA study suggest.
Exercise, Mediterranean diet remain key against MASLD
21 Jun 2024
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
20 Jun 2024
Physical activity substantially cuts cirrhosis risk in MASLD patients
A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
Physical activity substantially cuts cirrhosis risk in MASLD patients
19 Jun 2024
Novel miRNA signature reliably detects lethal pancreatic cancer in the early stages
An exosome-based liquid biopsy showed favourable signals for noninvasive, early detection of pancreatic ductal adenocarcinoma (PDAC) in a prospective study.